James R Eshleman

List of Publications by Year
in descending order

121 papers	34,560 citations	47 h-index	118 g-index
		47006	19190
123 all docs	123 docs citations	123 times ranked	38001 citing authors

#	Article	IF	Citations
1	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	27.0	7,696
2	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413.	12.6	4,945
3	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 2008, 321, 1801-1806.	12.6	3,755
4	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	27.8	2,700
5	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 2010, 467, 1114-1117.	27.8	2,184
6	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	27.8	2,132
7	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	27.8	1,741
8	Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene. Science, 2009, 324, 217-217.	12.6	713
9	Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Science Translational Medicine, 2011, 3, 92ra66.	12.4	703
10	Microsatellite Instability as a Biomarker for PD-1 Blockade. Clinical Cancer Research, 2016, 22, 813-820.	7.0	698
11	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21188-21193.	7.1	585
12	ATM Mutations in Patients with Hereditary Pancreatic Cancer. Cancer Discovery, 2012, 2, 41-46.	9.4	442
13	Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations. Journal of Molecular Diagnostics, 2010, 12, 425-432.	2.8	422
14	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications, 2015, 6, 7686.	12.8	393
15	LigAmp for sensitive detection of single-nucleotide differences. Nature Methods, 2004, 1, 141-147.	19.0	366
16	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	9.4	282
17	Conversion of diploidy to haploidy. Nature, 2000, 403, 723-724.	27.8	248
18	Comparison of the Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite Instability in Colorectal Cancers. Journal of Molecular Diagnostics, 2006, 8, 305-311.	2.8	234

#	Article	IF	Citations
19	Mismatch repair defects in human carcinogenesis. Human Molecular Genetics, 1996, 5, 1489-1494.	2.9	217
20	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	1.3	174
21	MutantGNASdetected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut, 2013, 62, 1024-1033.	12.1	160
22	Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Annals of Surgical Oncology, 2013, 20, 3802-3808.	1.5	158
23	Wholeâ€exome sequencing of pancreatic neoplasms with acinar differentiation. Journal of Pathology, 2014, 232, 428-435.	4.5	151
24	Detection of Microsatellite Instability by Fluorescence Multiplex Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2000, 2, 20-28.	2.8	133
25	Nanopore sequencing detects structural variants in cancer. Cancer Biology and Therapy, 2016, 17, 246-253.	3.4	130
26	Cytosine Deamination Is a Major Cause of Baseline Noise in Next-Generation Sequencing. Molecular Diagnosis and Therapy, 2014, 18, 587-593.	3.8	129
27	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 2018, 9, 28561-28571.	1.8	129
28	Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2014, 141, 856-866.	0.7	128
29	MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research, 2017, 23, 6863-6874.	7.0	122
30	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 4973-4984.	7.0	118
31	Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. Oncogene, 1998, 17, 719-725.	5.9	116
32	Verification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines. Journal of the National Cancer Institute, 2010, 102, 271-274.	6.3	116
33	Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer, 2015, 15, 779.	2.6	92
34	Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. Gastroenterology, 2019, 157, 838-850.e6.	1.3	88
35	Genetic and Epigenetic Alterations of Familial Pancreatic Cancers. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3536-3542.	2.5	79
36	Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia, 2016, 30, 1916-1920.	7.2	79

#	Article	IF	Citations
37	KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. Clinical Gastroenterology and Hepatology, 2015, 13, 963-969.e4.	4.4	74
38	Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget, 2015, 6, 42334-42344.	1.8	69
39	Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biology and Therapy, 2008, 7, 353-360.	3.4	67
40	Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4767-4772.	7.1	65
41	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Annals of Surgery, 2020, 272, 427-435.	4.2	61
42	Use of Single Nucleotide Polymorphisms (SNP) and Real-Time Polymerase Chain Reaction for Bone Marrow Engraftment Analysis. Journal of Molecular Diagnostics, 2000, 2, 202-208.	2.8	58
43	Leukemia Arising out of Paroxysmal Nocturnal Hemoglobinuria. Leukemia and Lymphoma, 1999, 32, 401-426.	1.3	57
44	Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Human Pathology, 2012, 43, 585-591.	2.0	56
45	Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Familial Cancer, 2015, 14, 95-103.	1.9	54
46	Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Modern Pathology, 2015, 28, 1390-1399.	5.5	53
47	Association of BRAF^{V600E} Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Thyroid, 2016, 26, 532-542.	4.5	50
48	Programmed death-1 blockade in mismatch repair deficient colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	1.6	50
49	Evaluation of the Cepheid GeneXpert BCR-ABL Assay. Journal of Molecular Diagnostics, 2007, 9, 220-227.	2.8	44
50	False Positives in Multiplex PCR-Based Next-Generation Sequencing Have Unique Signatures. Journal of Molecular Diagnostics, 2014, 16, 541-549.	2.8	43
51	Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool. American Journal of Clinical Pathology, 2015, 144, 620-628.	0.7	43
52	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 2017, 1-9.	3.0	42
53	Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer, 2019, 19, 665.	2.6	42
54	A protein therapeutic modality founded on molecular regulation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16206-16211.	7.1	41

#	Article	IF	Citations
55	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics, 2017, 19, 115-125.	2.8	41
56	Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 391-400.	2.8	39
57	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.. Journal of Clinical Oncology, 2016, 34, 195-195.	1.6	39
58	Nivolumab plus ipilimumab, with or without enzalutamide, in ARâ€V7â€expressing metastatic castrationâ€resistant prostate cancer: A phaseâ€2 nonrandomized clinical trial. Prostate, 2021, 81, 326-338.	2.3	35
59	Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma. Molecular Diagnosis and Therapy, 2014, 18, 409-418.	3.8	34
60	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 2021, 26, e270-e278.	3.7	33
61	Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget, 2017, 8, 96684-96696.	1.8	32
62	Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1989-1995.	2.0	31
63	Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using nextâ€generation sequencing. Cancer Cytopathology, 2016, 124, 744-753.	2.4	31
64	Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2020, 18, 1161-1169.e5.	4.4	31
65	PD-1 blockade in tumors with mismatch repair deficiency.. Journal of Clinical Oncology, 2015, 33, LBA100-LBA100.	1.6	31
66	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. Journal of Pathology, 2020, 252, 252-262.	4.5	30
67	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate, 2016, 76, 1484-1490.	2.3	29
68	Endocrine mucinâ€producing sweat gland carcinoma: A study of 11 cases with molecular analysis. Journal of Cutaneous Pathology, 2018, 45, 681-687.	1.3	28
69	Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma. Oncotarget, 2016, 7, 45237-45248.	1.8	25
70	Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice. Clinical Cancer Research, 2013, 19, 1139-1146.	7.0	24
71	Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle, 2017, 16, 991-998.	2.6	24
72	DNA Mismatch Repair Defects and Microsatellite Instability Status in Periocular Sebaceous Carcinoma. American Journal of Ophthalmology, 2014, 157, 640-647.e2.	3.3	23

#	Article	IF	Citations
73	The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Modern Pathology, 2020, 33, 2544-2563.	5.5	23
74	Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. American Journal of Clinical Pathology, 2016, 145, 696-702.	0.7	22
75	PD-1 blockade in tumors with mismatch repair deficiency.. Journal of Clinical Oncology, 2015, 33, LBA100-LBA100.	1.6	22
76	Morphology and genetics of pyloric gland adenomas in familial adenomatous polyposis. Histopathology, 2017, 70, 549-557.	2.9	20
77	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. BioMed Research International, 2016, 2016, 1-12.	1.9	19
78	JAK3 Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients. Cancer Prevention Research, 2019, 12, 255-270.	1.5	19
79	Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5035-5035.	1.6	19
80	A pilot study of prostateâ€specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate, 2019, 79, 1597-1603.	2.3	18
81	IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution. Cancer Medicine, 2020, 9, 4386-4394.	2.8	18
82	Application of Traditional Clinical Pathology Quality Control Techniques to Molecular Pathology. Journal of Molecular Diagnostics, 2008, 10, 142-146.	2.8	17
83	Î”-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations. Journal of Molecular Diagnostics, 2011, 13, 85-92.	2.8	17
84	Haplotype Counting by Next-Generation Sequencing for Ultrasensitive Human DNA Detection. Journal of Molecular Diagnostics, 2014, 16, 495-503.	2.8	17
85	Familial pancreatic cancer: from genes to improved patient care. Expert Review of Gastroenterology and Hepatology, 2007, 1, 81-88.	3.0	16
86	Lymph node metastases of melanoma: challenges for BRAF mutation detection. Human Pathology, 2015, 46, 113-119.	2.0	16
87	Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. Journal of Molecular Diagnostics, 2018, 20, 46-55.	2.8	16
88	Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. Archives of Pathology and Laboratory Medicine, 2019, 143, 174-182.	2.5	15
89	Tetraploid Partial Hydatidiform Moles. Journal of Molecular Diagnostics, 2020, 22, 90-100.	2.8	12
90	IDH1 and IDH2 Mutations in Colorectal Cancers. American Journal of Clinical Pathology, 2021, 156, 777-786.	0.7	12

#	Article	IF	Citations
91	HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer. Cancer Prevention Research, 2020, 13, 783-794.	1.5	11
92	Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Journal of Molecular Diagnostics, 2020, 22, 748-756.	2.8	11
93	Tandem Duplication PCR. Diagnostic Molecular Pathology, 2013, 22, 149-155.	2.1	10
94	Haplotype Counting for Sensitive Chimerism Testing. Journal of Molecular Diagnostics, 2017, 19, 427-436.	2.8	10
95	Clinical validation of coexisting driver mutations in colorectal cancers. Human Pathology, 2019, 86, 12-20.	2.0	10
96	Validation of Long Mononucleotide Repeat Markers for Detection of Microsatellite Instability. Journal of Molecular Diagnostics, 2022, 24, 144-157.	2.8	10
97	Advancements in the Development of HIF-1Î±-Activated Protein Switches for Use in Enzyme Prodrug Therapy. PLoS ONE, 2014, 9, e114032.	2.5	9
98	Transflip mutations produce deletions in pancreatic cancer. Genes Chromosomes and Cancer, 2015, 54, 472-481.	2.8	9
99	PINâ€like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations. Histopathology, 2021, 78, 327-333.	2.9	9
100	Alterations of type II classical cadherin, cadherinâ€10 (CDH10), is associated with pancreatic ductal adenocarcinomas. Genes Chromosomes and Cancer, 2017, 56, 427-435.	2.8	8
101	Pancreatic cancer pathology viewed in the light of evolution. Cancer and Metastasis Reviews, 2021, 40, 661-674.	5.9	7
102	Analysis of Hematopoietic Stem Cell Transplant Engraftment. Diagnostic Molecular Pathology, 2011, 20, 194-202.	2.1	6
103	Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens. American Journal of Clinical Pathology, 2019, 152, 570-581.	0.7	6
104	Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance. ELife, 2022, 11, .	6.0	6
105	Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. Human Pathology, 2022, 126, 63-76.	2.0	5
106	Anti-gene padlocks eliminate Escherichia coli based on their genotype. Journal of Antimicrobial Chemotherapy, 2008, 61, 262-272.	3.0	4
107	Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?. Human Pathology, 2020, 98, 120-128.	2.0	4
108	Comprehensive mutagenesis on yeast cytosine deaminase yields improvements in 5â€fluorocytosine toxicity in HT1080 cells. AICHE Journal, 2020, 66, e16688.	3.6	3

#	Article	IF	Citations
109	Clonal Origin Evaluated by Trunk and Branching Drivers and Prevalence of Mutations in Multiple Lung Tumor Nodules. Molecular Diagnosis and Therapy, 2020, 24, 461-472.	3.8	3
110	Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 400-411.	1.1	2
111	Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture. Pancreas, 2019, 48, 1225-1231.	1.1	2
112	Val16A SOD2 Polymorphism Promotes Epithelialâ€“Mesenchymal Transition Antagonized by Muscadine Grape Skin Extract in Prostate Cancer Cells. Antioxidants, 2021, 10, 213.	5.1	2
113	Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures. Pancreas, 2021, 50, 625-632.	1.1	2
114	A Cost-Effective and Non-Invasive pfeRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones. Non-coding RNA, 2021, 7, 80.	2.6	2
115	A New Fast Phasing Method Based On Haplotype Subtraction. Journal of Molecular Diagnostics, 2019, 21, 427-436.	2.8	1
116	Successful gene therapy requires targeting the vast majority of cancer cells. Cancer Biology and Therapy, 2020, 21, 946-953.	3.4	1
117	CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies. Clinical Chemistry, 2021, 67, 1524-1533.	3.2	1
118	Clinical utility of CLIA-grade AR-V7 testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 183-183.	1.6	1
119	Validation Strategy for Ultrasensitive Mutation Detection. Molecular Diagnosis and Therapy, 2018, 22, 603-611.	3.8	0
120	Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers. American Journal of Clinical Pathology, 2021, , .	0.7	0
121	Cost-benefit analysis of AR-V7 testing in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) eligible for abiraterone (Abi) or enzalutamide (Enza).. Journal of Clinical Oncology, 2016, 34, 283-283.	1.6	0